每經(jing)AI快(kuai)訊(xun)，迪瑞醫療（SZ 300396，收盤價(jia)(jia)：13.6元）5月8日(ri)晚(wan)間發布公(gong)(gong)告(gao)稱，持(chi)(chi)有公(gong)(gong)司(si)(si)股(gu)(gu)(gu)份(fen)(fen)33,123,600股(gu)(gu)(gu)（占公(gong)(gong)司(si)(si)總(zong)股(gu)(gu)(gu)本比(bi)例(li)12.15%）的(de)(de)股(gu)(gu)(gu)東廣東恒健國際(ji)投資有限公(gong)(gong)司(si)(si)（以下簡稱“恒健國際(ji)”）計劃以競價(jia)(jia)或大宗(zong)交(jiao)易(yi)方(fang)式(shi)減(jian)(jian)持(chi)(chi)公(gong)(gong)司(si)(si)股(gu)(gu)(gu)份(fen)(fen)總(zong)數不(bu)超過(guo)(guo)8,148,270股(gu)(gu)(gu)，減(jian)(jian)持(chi)(chi)比(bi)例(li)不(bu)超過(guo)(guo)公(gong)(gong)司(si)(si)總(zong)股(gu)(gu)(gu)本3%，自(zi)本減(jian)(jian)持(chi)(chi)計劃公(gong)(gong)告(gao)之日(ri)起十五個交(jiao)易(yi)日(ri)后的(de)(de)90日(ri)內實(shi)施。其中通(tong)過(guo)(guo)競價(jia)(jia)方(fang)式(shi)減(jian)(jian)持(chi)(chi)的(de)(de)，任(ren)意(yi)連續90個自(zi)然日(ri)內減(jian)(jian)持(chi)(chi)公(gong)(gong)司(si)(si)股(gu)(gu)(gu)份(fen)(fen)總(zong)數不(bu)超過(guo)(guo)2,710,630股(gu)(gu)(gu)，減(jian)(jian)持(chi)(chi)比(bi)例(li)不(bu)超過(guo)(guo)公(gong)(gong)司(si)(si)總(zong)股(gu)(gu)(gu)本的(de)(de)1%；通(tong)過(guo)(guo)大宗(zong)交(jiao)易(yi)方(fang)式(shi)減(jian)(jian)持(chi)(chi)的(de)(de)，任(ren)意(yi)連續90個自(zi)然日(ri)內減(jian)(jian)持(chi)(chi)公(gong)(gong)司(si)(si)股(gu)(gu)(gu)份(fen)(fen)不(bu)超過(guo)(guo)5,437,640股(gu)(gu)(gu)，減(jian)(jian)持(chi)(chi)比(bi)例(li)不(bu)超過(guo)(guo)公(gong)(gong)司(si)(si)總(zong)股(gu)(gu)(gu)本的(de)(de)2%。

2024年1至12月份，迪瑞醫(yi)療的營業收入構成為：醫(yi)療器械占(zhan)比99.52%，其他(ta)業務占(zhan)比0.48%。

截至發稿(gao)，迪瑞醫療市值(zhi)為37億(yi)元。

每經頭條（nbdtoutiao）——

（記者 王曉波）

免責聲明(ming)：本文內(nei)容與數據僅供參考，不(bu)構成投資建議，使用前請核(he)實(shi)。據此(ci)操作，風險自擔(dan)。